FREQUENCY OF DYSLIPIDEMIA IN MALE PATIENTS PRESENTING WITH ANDROGENIC ALOPECIA AT TERTIARY CARE HOSPITAL, KARACHI

Main Article Content

Vinesha Devi
Maria Naseer
Muneebah Siddiqi
Misbah Zakir Abowath
Ramla Moughal
Zarnaz Wahid

Keywords

Androgenic Alopecia, Dyslipidemia, Metabolic Syndrome, Triglyceride

Abstract

Because androgenetic alopecia is the most common cause of hair loss in men, it is sometimes referred to as "Common baldness." The disease has a polygenic inheritance pattern, and the main pathogenic event is the miniaturization of hair follicles. Androgen levels are often normal, indicating a role for end organ hyperreactivity to androgen, but androgenetic alopecia requires at least physiological amounts of circulating androgens to occur.


Objective: To determine the frequency of dyslipidemia in male patients presenting with androgenic alopecia at Dr. Ruth K.M Pfau Civil Hospital, Karachi.


Place and Duration: This Cross-Sectional Study was held in the Department of Dermatology, Dr. Ruth K.M Pfau Civil Hospital, Karachi, Pakistan for Six months after the approval of synopsis from May 31, 2021 to November 30, 2021.


METHODS: All patients who met the criteria of inclusion and visited Civil Hospital, Karachi were studied. After discussing the study's process, hazards, and benefits, informed consent was obtained. The blood sample was taken sterilely after a 12-hour overnight fast and labeled for dyslipidemia testing at a hospital laboratory. All obtained data were entered into the proforma at the end and used electronically for study.


Results: Mean ± SD of age was 46.9±7.9 years. Diabetes mellitus was documented in 45 (25.6%) patients. Dyslipidemia was found to be in 114 (64.8%) patients.


CONCLUSION: It is to be concluded that dyslipidemia is commonly prevalent in patients presenting with androgenic alopecia. More prospective and well-controlled clinical trials are needed to validate these findings.

Abstract 162 | pdf Downloads 34

References

1. Salman KE, Altunay IK, Kucukunal NA, Cerman AA. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital based cross- sectional study in Turkey. An Bras Dermatol 2017;92:35-40.
2. Milan DF. Risk factors in androgenetic alopecia in Nederland population. SanSan Poblish 2002;8:20-9.
3. Fortes, C, Mastroeni S, Mannooranparampil TJ, Ribuffo M. The combination of overweight and smoking increases the severity of androgenetic alopecia. Int J Dermatol 2017;56:862-67.
4. Kitagawa T, Matsuda K, Inui S, Takenaka H, Katoh N, Itami S, et al. Keratinocyte growth inhibition through the modification of wnt signaling by androgen in balding dermal papilla cells. J Clin Endocrinol Metab. 2009;94:1288-94.
5. Yeo IK, Jang WS, Min PK, Cho HR, Cho SW, Hong NS et al. An epidemiological study of androgenic alopecia in 3114 Korean patients. Clin Exp Dermatol 2014;39:25-29.
6. Kim MW, Shin IS, Yoon HS, Cho S, Park HS. Lipid profile in patients with androgenetic alopecia: a meta-analysis. J Eur Acad Dermatol Venereol 2017;31:942-51.
7. Rudnicka L, Rakowska A. Dyslipidemia in patients with androgenetic alopecia. Statins, finasteride or both? J Eur Acad Dermatol Venereol 2017;31:921-22.
8. Giltay EJ, Toorians AWFT, Sarabdjitsingh AR, Vries NA De, Gooren LJG. Established risk factors for coronary heart disease are unrelated to androgen induced baldness in female-to-male transsexuals. J Endocrinol 2004;180:107-12.
9. Mumcuoglu C, Ekmekci TR, Uca S. The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol 2011; 21:79-82.
10. Sadighha A, Zahed GM. Evaluation of lipid levels in androgenetic alopecia in comparison with control group. J Eur Acad Dermatol Venereol. 2009;23:80-1.
11. Al Sadat M, Ismail M, Elgendy A. dyslipidemia in patients with early onset androgenetic alopecia and risk of coronary disease. Gulf J Dermatol Vener. 2014;21:23-8.
12. Iram Qazi, Mohd Rafiq Tilwani, Nahida Nabi. Association of dyslipidemia and androgenetic alopecia: a case control study. Intern J Contemp Med Res 2019;6(7):G1-3.
13. Akin T, Kutlubay Z, Aşkın 0. The comparison of blood lipid profile in patients with and without androgenetic alopecia. J Turk Acad Dermatol 2020;14(1):12-8.
14. Biquees NA, Fatima K. Frequency of deranged blood lipids in male patients with androgenetic alopecia. J Pak Ass Derm 2018;28(4):406-9.
15. Arias-Santiago S, Gutiérrez-Salmerón MT, Buendía- Eisman A, Girón-Prieto MS, Naranjo- Sintes R. A comparative study of dyslipidemia in men and women with androgenetic alopecia. Acta Derm Venerol 2010;90:485-7.
16. Monib KM, Hussein MS, Kandeel WS. The relation between androgenetic thin hair diagnosed by trichoscope and benign prostatic hyperplasia. J Cosmet Dermatol. 2019;18 (5):1502-6.
17. Gordon SC, Abudu M, Zancanaro P, Ko JM, Rosmarin D. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2019;33(4):e156-7.
18. Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sütterlin M. Patient preferences regarding chemotherapy in metastatic breast cancer-a conjoint analysis for common taxanes. Front Oncol. 2018;8:535.
19. Li J, Kong XB, Chen XY, Zhong WZ, Chen JY, Liu Y, et al. Protective role of α2- macroglobulin against jaw osteoradionecrosis in a preclinical rat model. J Oral Pathol Med. 2019;48(2):166-73.
20. Lee YB, Jun M, Lee WS. Alopecia areata and poliosis: a retrospective analysis of 258 cases. J Am Acad Dermatol. 2019;80(6):1776-8.
21. Liu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. J Am Acad Dermatol. 2019;80(6):1778-9.
22. Chen P, Chen F, Zhou B. The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis. Cutan Ocul Toxicol. 2019;38(2):105-111.
23. Rinaldi F, Marzani B, Pinto D, Sorbellini E. Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata. J Dermatolog Treat. 2019;30(6): 588-93.
24. Owczarczyk-Saczonek A, Wygonowska E, Budkiewicz M, Placek W. Serum sickness disease in a patient with alopecia areata and Meniere' disease after PRP procedure. Dermatol Ther. 2019;32 (2):e12798.
25. Yu L, Lu Z. Linear alopecia areata. JAAD Case Rep. 2018;4(10):1072-3.
26. Davey L, Clarke V, Jenkinson E. Living with alopecia areata: an online qualitative survey study. Br J Dermatol. 2019;180(6):1377-89.